Zhen HUANG, Sheng-Lin WANG, Qing-Shan HUANG, Xiao-Dong Lİ, Hui CHEN, Jian-Hua LİN

Clinicopathological value of ErbB2 gene and protein expression in osteochondroma

Objective: The aim of this study was to investigate ErbB2 expression in osteochondroma and its relationship with clinicopathologic features of osteochondroma, so as to identify a new biomarker for the malignant transformation potential of osteochondroma. Methods: Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were used to investigate the expression status of ErbB2 protein and gene in 30 osteochondroma tissues and 20 non-neoplastic bone tissues. The association of ErbB2 gene and protein expression with clinicopathological parameters of osteochondroma was analyzed by using the χ2 test and Fishers exact test. Results: ErbB2 protein was found to be over-expressed in 4 of 30 (13.3%) osteochondromas and 1 of 20 (5%) non-neoplastic bone samples, which were not statistically significant (p=0.336). However, 13 of the 30 (43.3%) osteochondromas showed ErbB2 gene amplification, which was failed to be observed in any of the non-neoplastic bone tissue. ErbB2 gene amplification in osteochondroma was significantly higher compared with that in non-neoplastic bone tissue (p=0.001). In addition, the ErbB2 gene amplification was closely associated with clinical pathological parameters of osteochondroma, including high expression of cellularity (p=0.001), presence of binucleated cells (p=0.001), nuclear pleomorphism (p=0.003), calcification (p=0.002), nodularity (p=0.002), necrosis (p=0.009) and cartilage thickness (p=0.026). The association of the gene amplification with other clinicopathological parameters of osteochondroma, including permeation of trabecular bone, cystic/mucoid changes, mitosis, radiographic appearance, cap volume and subtype of osteochondroma was not observed. The over-expression of ErbB2 protein was not found to be associated with the above stated clinical pathological parameters of osteochondroma. Conclusion: ErbB2 gene amplification was associated with adverse clinicopathological status of osteochondroma and could serve as an index for malignant conversion of osteochondroma. Further research is required to verify the predictive values of ErbB2 for osteochondroma.

___

Shim JH, Park CK, Shin SH, Jeong HS, Hwang JH. Solitary osteochondroma of the twelfth rib with intraspinal extension and cord compression in a middle-aged patient. BMC Musculoskelet Disord 2012; 13: 57. [CrossRef]

Argyriou C, Drosos G, Tottas S, Tasopoulou KM, Kougioumtzis I, Georgiadis GS. A rare case of tibioperoneal arterial trunk entrapment caused by a fibular osteochondroma. Ann Vasc Surg 2019; 55: 308. [CrossRef]

Kim SR, Kim TJ, Seo KB. Osteochondroma of the radial tuberosity in child. J Hand Surg Asian Pac Vol 2016; 21: 103-8. [CrossRef]

Cho HS, Han I, Kim HS. Secondary chondrosarcoma from an osteochondroma of the proximal tibia involving the fibula. Clin Orthop Surg 2017; 9: 249-54. [CrossRef]

Bovee JV. Multiple osteochondromas. Orphanet J Rare Dis 2008; 3: 3. [CrossRef]

Gitelis SJR. Bone and soft tissue tumors: Clinical features, imaging, pathology and treatment. 2nd ed. Radiology 2001; 83: 236. [CrossRef]

Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-9. [CrossRef]

Kersting C, Gebert C, Agelopoulos K, et al. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res 2007; 13: 2998-3005. [CrossRef]

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82. [CrossRef]

10. Liu Y, Ma YH, Sun ZZ, et al. Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies. Tumour Biol 2014; 35: 8939-43. [CrossRef]

11. Olsen RJ, Lydiatt WM, Koepsell SA, et al. C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. Head Neck 2005; 27: 883-92. [CrossRef]

12. Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2 (HER2) -Specific chimeric antigen receptor-modif ied T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015; 33: 1688-96. [CrossRef]

13. Srirajaskanthan R, Shah T, Watkins J, Marelli L, Khan K, Caplin ME. Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours. Oncol Rep 2010; 23: 909-15. [CrossRef]

14. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000; 53: 374-81. [CrossRef]

15. Guo Q, Fang Z, Li Y, Xu Y, Guan H, Li F. Treatment of spinal cord compression caused by C2 osteochondroma with reconstruction and fusion after total resection: Case report and literature review. J Spinal Cord Med 2018: 1-6. [CrossRef]

16. Lee AK, Woll AK, Malone WJ, Mirenda WM. Trauma-induced resolution of solitary osteochondroma of the distal femur. Orthopedics 2016; 39: e1001-4. [CrossRef]

17. Errani C, Vanel D, Donati D, Picci P, Faldini C. Spontaneous healing of an osteochondroma fracture. Diagn Interv Imaging 2015; 96: 2835. [CrossRef]

18. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001; 14: 1277-83. [CrossRef]

19. Radenkovic S, Konjevic G, Isakovic A, Stevanovic P, Gopcevic K, Jurisic V. HER2-positive breast cancer patients: Correlation between mammographic and pathological findings. Radiat Prot Dosimetry 2014; 162: 125-8. [CrossRef]

20. Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Bilancio A, Migliaccio A. The androgen receptor in breast cancer. Front Endocrinol (Lausanne) 2018; 9: 492. [CrossRef]

21. Rodallec A, Brunel JM, Giacometti S, et al. Docetaxel-trastuzumab stealth immunoliposome: Development and in vitro proof of concept studies in breast cancer. Int J Nanomedicine 2018; 13: 3451-65. [CrossRef]

22. Eefting D, Schrage YM, Geirnaerdt MJ, et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol 2009; 33: 50-7. [CrossRef]

23. Piombo V, Jochmann K, Hoffmann D, Wuelling M, Vortkamp A. Signaling systems affecting the severity of multiple osteochondromas. Bone 2018; 111: 71-81. [CrossRef]

24. de Andrea CE, Kroon HM, Wolterbeek R, et al. Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas. Mod Pathol 2012; 25: 127583. [CrossRef]

25. Bernard SA, Murphey MD, Flemming DJ, Kransdorf MJ. Improved differentiation of benign osteochondromas from secondary chondrosarcomas with standardized measurement of cartilage cap at CT and MR imaging. Radiology 2010; 255: 857-65. [CrossRef]

26. Huang S, Li C, Armstrong EA, et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013; 73: 824-33. [CrossRef]

27. Perez EA, Press MF, Dueck AC, et al. Immunohistochemistry and f luorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 2013; 138: 99-108. [CrossRef]

28. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 358: 1409-11. [CrossRef]

29. Mattsson JS, Brunnström H, Jabs V, et al. Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. BMC Cancer 2016; 16: 603. [CrossRef]